A new series of lipocrine derivatives has been designed by replacing the antioxidant alfa lipoic residue with carbazole moiety of carvedilol.

Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Tarozzi a, et al. (2007). Multitarget-directed drug design strategy: novel hybrid compounds between lipocrine and carvedilol. s.l : s.n.

Multitarget-directed drug design strategy: novel hybrid compounds between lipocrine and carvedilol

ROSINI, MICHELA;SIMONI, ELENA;BOLOGNESI, MARIA LAURA;ANDRISANO, VINCENZA;BARTOLINI, MANUELA;TAROZZI, ANDREA;HRELIA, PATRIZIA;MELCHIORRE, CARLO
2007

Abstract

A new series of lipocrine derivatives has been designed by replacing the antioxidant alfa lipoic residue with carbazole moiety of carvedilol.
2007
Programme and Abstracts 16th Camerino-Noordwijkrhout symposium "An overview of receptor chemistry
83
83
Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Tarozzi a, et al. (2007). Multitarget-directed drug design strategy: novel hybrid compounds between lipocrine and carvedilol. s.l : s.n.
Rosini M; Simoni E; Bolognesi ML; Andrisano V; Bartolini M; Tarozzi a; Hrelia P; Mellor I; Melchiorre C.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/47561
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact